Company intelligence / Profile preview

VioQuest Pharmaceuticals, Inc.

Basking Ridge, New Jersey, United Statesbiospace.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company was developing multiple clinical-stage drug therapies, including Xyfid for hand-foot syndrome, VQD-002 (a nucleoside analog) for cancer treatment, and Lenocta (a small molecule inhibitor) for melanoma, renal cell carcinoma, and other solid tumors. Triciribine Phosphate reached Phase 2 for ovarian cancer.

Therapeutic areas: OncologyDermatologyInfectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

3 assets

Xyfid

Phase 2

Indications: Hand-foot syndrome, Dermatoses

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on VioQuest Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VioQuest Pharmaceuticals, Inc..

Explore the full profile